BAS:XETR

BASF SE

Data as of 2026-03-10 - not real-time

€44.79

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

BASF shares are trading at €44.79, barely above the computed support level of €43.90. The 20‑day SMA sits at €48.71, indicating the price is still below short‑term averages. Momentum indicators are mixed: the RSI of 35 suggests the stock is approaching oversold territory, while the MACD histogram remains negative, signaling bearish pressure. Despite these technical headwinds, the overall trend direction is flagged as bullish and volume is increasing, hinting at accumulating interest. The dividend yield stands at an attractive 4.97% with a payout ratio of just 6.6%, underscoring strong cash generation. However, the trailing P/E of 132 is extreme, reflecting a current earnings shortfall.
Forward‑looking metrics are more encouraging, with a forward P/E near 15 and projected EPS rising from €0.34 to €3.06, implying a substantial earnings rebound. Analyst consensus (21 analysts) rates the stock as a “buy” with a median target of €52, offering roughly an 11% upside from today’s price. The company’s balance sheet shows ample cash (€4.09 bn) against debt of €23.2 bn, resulting in a moderate debt‑to‑equity of 68%, which is manageable given its cash flow. The chemical sector is exposed to regulatory and commodity price cycles, adding medium‑level sector risk. BASF’s low beta and diversified global footprint temper overall volatility, though recent 30‑day price swings exceed 30%, indicating heightened short‑term risk. In this context, the stock appears fairly valued with a blend of growth and value attributes, supported by a sustainable dividend.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 6/10

Key Factors

  • Price near support with limited upside
  • RSI indicating oversold conditions
  • Bearish MACD histogram

Medium Term

1–3 years
buy
Conviction: 8/10

Key Factors

  • Forward earnings growth and reasonable forward P/E
  • Attractive dividend yield with low payout ratio
  • Analyst target price suggesting ~11% upside

Long Term

> 3 years
buy
Conviction: 7/10

Key Factors

  • Sustainable dividend supported by strong cash flow
  • Diversified global chemical portfolio
  • Manageable debt level relative to cash reserves

Key Metrics & Analysis

Financial Health

Revenue Growth-5.60%
Profit Margin2.71%
P/E Ratio131.7
ROE4.33%
ROA1.97%
Debt/Equity67.59
P/B Ratio1.2
Op. Cash Flow€5.6B
Free Cash Flow€357.1M

Technical Analysis

TrendBullish
RSI35.1
Support€43.90
Resistance€52.68
MA 20€48.71
MA 50€46.90
MA 200€44.39
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Target Price€49.79
Upside/Downside11.15%
GradeFair
TypeBlend
Dividend Yield4.97%

Risk Assessment

Beta0.20
Volatility30.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.